BTSG — BrightSpring Health Services, Inc. Common Stock

Summary of BrightSpring Health Services, Inc. Q1 2026 Earnings Call

1. Key Financial Results and Metrics

• Total Revenue: $3.6 billion, up 26% year-over-year.
• Pharmacy Solutions Revenue: $3.2 billion, a 25% increase.
• Provider Services Revenue: $442 million, representing 28% growth.
• Adjusted EBITDA: $190 million, a 45% increase, with a margin of 5.3%, up 70 basis points year-over-year.
• Cash Flow from Operations: $123 million, excluding Community Living divestiture fees.
• Leverage Ratio: 2.27x, down from 2.99x as of December 31, 2025.
• Adjusted EPS: $0.39.

2. Strategic Updates and Business Highlights

• BrightSpring continues to lead in home and community health services, focusing on high-quality care for complex patients.
• The company is integrating acquired Amedisys and LHC branches, expecting a $30 million EBITDA contribution in the first year.
• Pharmacy Solutions showed strong growth in specialty and infusion businesses, with a focus on expanding geographic reach and improving patient satisfaction.
• Home Health reported significant growth due to market share gains and successful integration of acquired branches, with 49% revenue growth.
• Quality metrics remain strong across services, with high patient satisfaction scores and timely care initiation.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Expected to be between $14.725 billion and $15.225 billion, reflecting 14.1% to 17.9% growth over 2025.
• Adjusted EBITDA Guidance: Projected between $795 million and $825 million, indicating growth of 28.7% to 33.6% over 2025.
• Anticipated ongoing revenue impact from the IRA, estimated at $175 million for Home and Community Pharmacy and $181 million for Specialty and Infusion.

4. Bad News, Challenges, or Points of Concern

• IRA Impact: The IRA is expected to continue affecting revenues, particularly in Home and Community Pharmacy, with a projected $175 million impact for 2026.
• Home and Community Pharmacy Decline: Revenue decreased by 9% year-over-year due to IRA impacts and exiting uneconomic customers.
• Competitive Pressures: Concerns regarding PBM dynamics and private label biosimilars, although current exposure is limited.
• Corporate Costs Increase: SG&A expenses rose significantly, attributed to investments in IT and salesforce, which may impact margins if not managed effectively.

5. Notable Q&A Insights

• Management expressed confidence in the growth of the Infusion business, with double-digit growth expected in both acute and chronic segments.
• The company is exploring value-based care arrangements in Medicare, with optimism about potential cost reductions and improved care delivery.
• Specialty script growth was approximately 30% year-over-year, with ongoing efforts to expand market share in oncology and other therapeutic areas.
• The management team remains cautious about future M&A, aiming to maintain leverage under 3x while focusing on smaller, strategic acquisitions.
• Operational efficiencies and AI applications are being prioritized to enhance workflow and reduce costs, with ongoing projects expected to yield benefits over time.

Overall, BrightSpring Health Services reported strong financial performance in Q1 2026, driven by strategic growth initiatives and operational efficiencies, while facing challenges from regulatory impacts and competitive pressures.